Skip to main content
Clinical Trials/NCT03102749
NCT03102749
Completed
Not Applicable

Mechanism and Dynamics of Bronchial Hyper-reactivity to Methacholine in Distal Airway on Obese Patients With Asthma

University Hospital, Montpellier1 site in 1 country35 target enrollmentJune 2012
ConditionsAsthma

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Asthma
Sponsor
University Hospital, Montpellier
Enrollment
35
Locations
1
Primary Endpoint
Change in inspiratory:expiratory mean lung density
Status
Completed
Last Updated
6 years ago

Overview

Brief Summary

New insights of small airway contribution to asthma have been gained. Poor levels of control and recurrent exacerbations were shown to have the phenotypic counterpart of asthma with predominant small airway involvement. Very few pathological specificities were identified at this site: mast cells infiltration was suggested as the specific inflammatory change when compared to the proximal airways.Biomarkers in asthma are still complex to validate, especially in the blood, since compartmentalisation is intense in the lung and the airways, a property attributed to the filtering role of the lung to maintain homeostasis. Over the last few years, Fraction exhaled Nitric Oxide (FENO) was developed as a non-invasive and indirect reflection of airway eosinophilic inflammation]. In the blood, peripheral eosinophil counts were shown as a correct T helper 2 (TH2)-phenotype identifier but not perfectly related to airway eosinophilic infiltration. Club cell secretory protein (SCGB1A1) levels have been shown to have some relevance in asthma, chronic obstructive pulmonary disease (COPD), BOS, sarcoidosis, and lung cancer.A biomarker for small airway disease in asthma may improve the management of the disease, identify areas of therapeutic resistance and constitute a therapeutic guidance tool. In this study, investigators aimed to assess small airway involvement in asthmatic women as far as they could. For this purpose, investigators analysed trends in air trapping by acquiring expiratory CT slices at each dose during a bronchoprovocation test with metacholine. Biomarkers were subsequently tested and confronted to clinical and demographical characteristics in their ability to predict the small airway involvement index obtained at CT.

Detailed Description

Patients will be recruited in the respiratory department of University Hospital in Montpellier (France) from June 2012 to March 2014. All patients are asthmatics, in order to avoid any gender-related biases, investigators decided to include only women. All participants had normal range spirometry, specifically regarding forced expiratory volume. Each patient will undergo a bronchial provocation test coupled with a thoracic CT scan. Bronchial and alveolar Nitric Oxyde will also be measured, a blood sample will be obtained in order to measure biomarker concentrations, and the patients will be asked to answer the validated Asthma Control Questionnaire in order to quantify asthma control.

Registry
clinicaltrials.gov
Start Date
June 2012
End Date
December 2014
Last Updated
6 years ago
Study Type
Observational
Sex
Female

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Female \>= 18 yrs
  • Treated with Inhaled Corticosteroid (ICS)
  • normal range spirometry

Exclusion Criteria

  • Patients with other respiratory disease
  • Patients with myocardial infarction (for 3 month before enrollment)
  • Patients with cerebrovascular accident (for 3 month before enrollment)
  • Patients with arterial aneurysm known
  • Patients in pregnancy
  • Patients nursing

Outcomes

Primary Outcomes

Change in inspiratory:expiratory mean lung density

Time Frame: 4 hours (after the enrollment)

Baseline versus post-methacholine challenge

Secondary Outcomes

  • FeNO(Baseline)
  • FaNO(Baseline)
  • Change in lung fractal dimension(4 hours (after the enrollment))
  • Bronchial morphometry(Baseline)
  • CC10 level(Baseline)

Study Sites (1)

Loading locations...

Similar Trials